BioSpace News Archive

Harbour BioMed announced it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer treatment.

Metabolism of the human body relies on a variety of factors, and proper metabolism is essential to prevent several diseases.

Neonatal care equipment are usually provided to preterm infants or newborn infants whose medical conditions are severe.

Microbial identification has become an important aspect of the overall healthcare domain. With the growing prevalence of infectious diseases, increasing frequency of global pandemic, and rising food safety concerns the need for rapid and reliable microbial identification has become highly important.

The demand within the global femoral head prostheses market is rising on the back of continuous advances in materials and performance of medical implants.

Cardiac Assist Devices are a type of mechanical pumps that work along with the heart to improve its pumping efficiency and maintain optimum blood flow throughout the body.

Fact.MR, Dubai: As per a study by Fact.MR, the global primary cell culture market is anticipated to expand at a growth rate of 11.6% CAGR over the forecast period, starting from 2021 to 2031.

The global analytical standards market provides increasing public concerns related to optimum food quality and safety, increasing applications of different analytical techniques in proteomics & metabolomics, and better regulatory emphasis on efficient pollution control and monitoring are some of the important factors driving the growth of the analytical standards market.

Patrys Limited, a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic antibody candidate PAT-DX1 in The Journal of Clinical Investigation—Insight.

MannKind Corporation and United Therapeutics Corporation reached a major milestone with the announcement that the U.S. Food and Drug Administration accepted for priority review of the New Drug Application for Tyvaso DPI™ for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.